ATC Group: C01CA03 Norepinephrine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C01CA03 in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C01 Cardiac therapy
3 C01C Cardiac stimulants excl. cardiac glycosides
4 C01CA Adrenergic and dopaminergic agents
5 C01CA03 Norepinephrine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
PAREN - Parenteral 6 mg

Active ingredients in C01CA03

Active Ingredient Description
Noradrenaline

Noradrenaline provides a strong stimulation of alpha receptors in blood vessels at which these are counter-extracted. Noradrenaline also has an effect on beta-1 receptors in the heart leading to a positive inotropic and initially positive chronotropic effect. The increase in blood pressure may cause a reflex reduction in heart rate.

Related product monographs

Title Information Source Document Type  
MYKRONOR Solution for injection / infusion Health Products Regulatory Authority (IE) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Austria (AT)

Brazil (BR)

Canada (CA)

Croatia (HR)

Ecuador (EC)

Hong Kong (HK)

Ireland (IE)

Netherlands (NL)

New Zealand (NZ)

Poland (PL)

Romania (RO)

Singapore (SG)

Spain (ES)

Tunisia (TN)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.